Victoria Eatwell Sells 2,592 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

2seventy bio, Inc. (NASDAQ:TSVT) CFO Victoria Eatwell sold 2,592 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $4.95, for a total value of $12,830.40. Following the transaction, the chief financial officer now owns 444,387 shares in the company, valued at approximately $2,199,715.65. This represents a 0.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

2seventy bio Stock Performance

Shares of NASDAQ TSVT opened at $4.95 on Friday. The company has a market cap of $255.36 million, a PE ratio of -2.66 and a beta of 1.73. The business has a 50-day simple moving average of $2.94 and a two-hundred day simple moving average of $3.71. 2seventy bio, Inc. has a fifty-two week low of $2.29 and a fifty-two week high of $5.99.

Institutional Investors Weigh In On 2seventy bio

Several institutional investors have recently added to or reduced their stakes in TSVT. Bank of America Corp DE boosted its holdings in 2seventy bio by 317.1% in the fourth quarter. Bank of America Corp DE now owns 2,515,897 shares of the company’s stock worth $7,397,000 after acquiring an additional 1,912,771 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of 2seventy bio during the fourth quarter worth about $3,689,000. Toronto Dominion Bank acquired a new stake in shares of 2seventy bio during the fourth quarter worth about $2,352,000. Western Standard LLC lifted its holdings in shares of 2seventy bio by 175.7% during the fourth quarter. Western Standard LLC now owns 788,350 shares of the company’s stock worth $2,318,000 after purchasing an additional 502,419 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in shares of 2seventy bio during the fourth quarter worth about $913,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on TSVT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a research note on Friday, March 7th. Leerink Partners reiterated a “market perform” rating and issued a $5.00 target price (down previously from $9.00) on shares of 2seventy bio in a research note on Tuesday, March 11th. Leerink Partnrs lowered 2seventy bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 11th. Finally, Morgan Stanley cut their target price on 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.67.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.